UK Defence Secretary Questions 5m Donation to Reform UK Leader Over Potential RussiaLinked Profits SoftBank Group Surges 61 Billion in Market Cap Over Two Days on AI Optimism Quantum and Destinus Reportedly in Early IPO Preparations for 2027 American Graphics Signs Expands Fleet Graphics Installation Network to All 50 States Cigna Group Downgraded to Hold by Deutsche Bank Amid MultiYear Portfolio Uncertainty SpaceX and OpenAI MegaIPOs Could Signal Potential Market Peak Analysts Suggest VIA Q1 2026 Earnings NarrowerThanExpected Loss Sends Shares Higher SCM Q1 2026 Earnings EPS Misses Estimates by Narrow Margin Stock Declines ZURA Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Stage RCAT Q1 2026 Earnings Negative EPS Surprise as Strategic Initiatives Continue PRTA Q1 2026 Earnings Biotech Surprises with Positive EPS on Milestone Gain Stock Rises CDNA Q1 2026 Earnings Major EPS Beat Signals StrongerThanExpected Profitability National Storage Affiliates Trust NSA Rises Slightly as Support Holds Key Levels in Focus Duke Energy Preferred DUKB Edges Higher Holding Above Key Support Level Star Bulk Carriers SBLK Holds Steady Near Support After Minor Pullback FibroBiologics Inc FBLG Rallies 57 as Shares Test Key Resistance at 118 CoStar Group Inc CSGP Declines Over 4 as Selling Pressure Intensifies SpaceXs Potential 175 Trillion IPO Historical Patterns Suggest Possible Decline Nasdaq Inc Q1 2026 Earnings EPS Slightly Exceeds Street Estimates Amid Steady Performance Invesco Quality Municipal Income Trust IQI Gains Ground as Bond Markets Stabilize AWR Q1 2026 Earnings EPS Misses Estimates by 228 Stock Gains 08 BioRad Q1 2026 Earnings Earnings Miss Estimates Despite Stock Rally Minerva Neurosciences Inc NERV Q1 2026 Earnings Wider Loss Highlights Ongoing PreRevenue Development Stage TALK Q1 2026 Earnings Significant EPS Miss Amid Operational Uncertainty SRE Q1 2026 Earnings EPS Slightly Misses Estimates Shares Rise Aqua Metals Q3 2025 Earnings EPS Misses Estimates by Wide Margin Amid Continued Operational Challenges ASND Q1 2026 Earnings EPS Misses Estimates as Ascendis Pharma Navigates Cost Pressures